Investment Thesis
MYOMO demonstrates strong revenue growth (25.7% YoY) and exceptional gross margins (68.2%), indicating viable product-market fit in the orthopedic device sector. However, deteriorating profitability with negative operating cash flow (-$2.2M), expanding net losses despite revenue growth (EPS -131.2% YoY), and elevated leverage (1.21x Debt/Equity) create material financial risk, particularly concerning for an unprofitable medical device company burning cash.
Strengths
- Strong top-line growth at 25.7% YoY indicates market traction and demand for orthopedic products
- Exceptional gross margin of 68.2% demonstrates strong pricing power and/or manufacturing efficiency
- Adequate liquidity position with 2.73x current ratio and $11.4M cash reserves relative to $36.8M total assets
Risks
- Worsening profitability: losses expanded despite revenue growth (EPS down 131.2% YoY), indicating negative operating leverage and cost control failure
- Negative operating and free cash flow (-$2.2M OCF, -$2.5M FCF) with ~4.5 year cash runway at current burn rate in an unprofitable state
- Elevated leverage (1.21x Debt/Equity, $10.9M long-term debt) combined with negative earnings and cash burn creates solvency risk if losses persist
Key Metrics to Watch
- Operating cash flow trajectory - must inflect positive to validate business model sustainability
- Operating margin expansion path - current -31.2% margin must compress significantly for profitability
- Cash burn rate and runway - monitor if burn accelerates beyond current $2.5M annual FCF consumption rate
- Revenue growth deceleration impact - assess whether 25.7% growth can be sustained and if it generates positive cash at scale
Financial Metrics
Revenue
10.1M
Net Income
-3.0M
EPS (Diluted)
$-0.07
Free Cash Flow
-2.5M
Total Assets
36.8M
Cash
11.4M
Profitability Ratios
Gross Margin
68.2%
Operating Margin
-31.2%
Net Margin
-29.8%
ROE
-33.4%
ROA
-8.2%
FCF Margin
-25.0%
Balance Sheet & Liquidity
Current Ratio
2.73x
Quick Ratio
2.36x
Debt/Equity
1.21x
Debt/Assets
75.5%
Interest Coverage
-14.43x
Long-term Debt
10.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:29:12.635068 |
Data as of: 2026-03-31 |
Powered by Claude AI